Guggenheim assumed coverage on shares of Forty Seven (NASDAQ:FTSV) in a research note published on Wednesday, FinViz reports. The firm issued a buy rating and a $20.00 price target on the stock.

FTSV has been the topic of a number of other research reports. Mizuho restated a buy rating and issued a $18.00 price objective on shares of Forty Seven in a report on Tuesday, November 12th. ValuEngine upgraded Forty Seven from a hold rating to a buy rating in a report on Friday, August 16th. Oppenheimer reduced their price target on Forty Seven from $35.00 to $20.00 in a report on Wednesday, August 14th. HC Wainwright reiterated a buy rating and set a $21.00 price target on shares of Forty Seven in a report on Wednesday, November 13th. Finally, Zacks Investment Research lowered Forty Seven from a hold rating to a sell rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $22.75.

FTSV stock traded up $0.14 during midday trading on Wednesday, reaching $12.19. The stock had a trading volume of 244,900 shares, compared to its average volume of 219,227. The company’s fifty day simple moving average is $7.22 and its 200 day simple moving average is $9.33. The company has a current ratio of 7.48, a quick ratio of 7.48 and a debt-to-equity ratio of 0.01. The company has a market cap of $451.93 million, a price-to-earnings ratio of -3.25 and a beta of 1.90. Forty Seven has a 52-week low of $5.53 and a 52-week high of $23.83.

Forty Seven (NASDAQ:FTSV) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.38) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.38). The firm had revenue of $15.68 million during the quarter, compared to analysts’ expectations of $15.80 million. Sell-side analysts predict that Forty Seven will post -2.63 EPS for the current year.

In other news, Director Ravindra Majeti sold 15,000 shares of Forty Seven stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.26, for a total transaction of $153,900.00. Following the transaction, the director now owns 1,221,400 shares in the company, valued at approximately $12,531,564. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 37.40% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. River & Mercantile Asset Management LLP purchased a new stake in Forty Seven in the 2nd quarter valued at about $35,000. Tower Research Capital LLC TRC raised its holdings in Forty Seven by 5,976.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 4,132 shares of the company’s stock valued at $27,000 after buying an additional 4,064 shares during the period. Metropolitan Life Insurance Co NY purchased a new stake in Forty Seven in the 1st quarter valued at about $88,000. Vanguard Group Inc. raised its holdings in Forty Seven by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 499,451 shares of the company’s stock valued at $5,294,000 after buying an additional 5,741 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Forty Seven by 18.3% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 37,899 shares of the company’s stock valued at $402,000 after buying an additional 5,867 shares during the period. Hedge funds and other institutional investors own 38.11% of the company’s stock.

Forty Seven Company Profile

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Read More: What are the benefits of buying treasury bonds?

Analyst Recommendations for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.